Effects of cyclosporine in severe systemic lupus erythematosus

Feutren, G.; Quérin, Serge; Nôël, Laure-Hélène; Chatenoud, Lucienne; Beaurain, Geneviève; Tron, François; Lesavre, P; Bach, Jean‐François

doi:10.1016/s0022-3476(87)80057-4

Cited by 64 publications

(25 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A decrease in autoantibody titers in patients treated with CSA has previously been reported by Miescher and Miescher (15) and Tokuda et al (16), whereas Feutren et a1 (17) showed that in spite of clinical improvement, titers of both ANA and antidsDNA antibodies remained unchanged after 6 months of CSA therapy. Even in animal models of SLE, con-flicting results regarding the response of autoantibodies to CSA have been reported.…”

Section: Discussionsupporting

confidence: 58%

See 1 more Smart Citation

Long‐term treatment of systemic lupus erythematosus with cyclosporin A

Caccavo

Laganà

Mitterhofer

et al. 1997

Arthritis & Rheumatism

100

View full text Add to dashboard Cite

Objective. To evaluate the efficacy of long-term treatment with cyclosporin A (CSA) in systemic lupus erythematosus (SLE).Methods. Thirty patients with SLE whose condition was either poorly responsive or unresponsive to treatment with steroids and/or cytotoxic drugs were enrolled in a prospective, nonrandomized study of CSA. Patients with hypertension or hypercreatinemia were excluded. Disease activity was evaluated according to the systemic lupus activity measure. Assessments were made prior to study entry and after 6, 12, 18, and 24 months.Results. Twenty-seven patients completed at least 24 months of treatment with CSA. The mean disease activity score significantly decreased after 6 months of therapy (P < 0.01); this result was maintained throughout the study. A conspicuous steroid-sparing effect was observed following administration of CSA (P < 0.01).Side effects included hypertrichosis (63% of patients), paresthesias (23%), gastrointestinal symptoms (ZWo), gingival hyperplasia (17%), hypertension (lWo), tremors (7%), and nephrotoxicity (13%). No significant changes in serum creatinine levels were observed.Conclusion. CSA represents a helpful secondchoice treatment for patients with active SLE. Administration of CSA necessitates expert and careful followup of patients.Systemic lupus erythematosus (SLE), particularly in its severe form, still represents a major therapeutic Supported in part by a grant from Minister0

show abstract

Section: Discussionsupporting

confidence: 58%

“…In fact, Miescher and Miescher (15) and Feutren et a1 (17) have reported that CSA is effective in improving disease activity in patients with severe steroid-resistant or steroid-dependent SLE. These authors also demonstrated that CSA allowed the amount of steroid required to control the clinical manifestations to be reduced.…”

Section: Discussionmentioning

confidence: 99%

Long‐term treatment of systemic lupus erythematosus with cyclosporin A

Caccavo

Laganà

Mitterhofer

et al. 1997

Arthritis & Rheumatism

100

View full text Add to dashboard Cite

show abstract

“…] has led to clinical trials in the treatment ofautoimmune diseases [2]. Knowledge of the cellular and molecular mechanisms by which immunosuppression and toxic side effects of CsA are mediated is evolving, Cyclophilin-I8 (CyP-18) is a small (mol.…”

Section: Introductionmentioning

confidence: 99%

Autoantibodies against cyclophilin in systemic lupus erythematosus and Lyme disease

Kratz

Harding

Craft

et al. 1992

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SUMMARYAutoantibodies against cyclophiiiti, a cyclosporin A binding protein, were detected in sera of 29 of 46 (63%) patients with systemic lupus erythematosus and 14 of 40 (35%) Lyme disease patients. The antibodies are directed against the denatured form of both the major and minor isoform of cyclophilin and can be demonstrated in Western blots. Some lirst-degree relatives of lupus patients also e.xpress these antibodies. They are specific for cyclophilin and are not the consequence of hypergammaglobulinaemia. Four monoclonal IgM antibodies from a patient with lepromatous leprosy also bound to cyclophilin. The generation of these antibodies may be of special interest because they are against a protein involved in the control ofthe immune system not known to be directly associated with DNA or RNA,

show abstract

“…It has been shown that CsA therapy reduces proteinuria in membranous LN [3,13] , but there is little data on its effect on proliferative LN. Two studies have shown that CsA can significantly reduce proteinuria, overall disease activity, and improve renal function [7,8] .…”

Section: Discussionmentioning

confidence: 99%

Treatment of Lupus Nephritis with Cyclosporine – An Outcome Analysis

Rihova

Vankova

Maixnerová

et al. 2007

Kidney Blood Press Res

View full text Add to dashboard Cite

Background: The optimal therapy for lupus nephritis (LN), including the role of cyclosporine (CsA), still lacks scientifically valid clinical experience. We evaluated the efficacy of CsA in the induction and maintenance treatment of patients with biopsy-proven LN. Patients and Methods: A total of 31 patients (25 women, 6 men, mean age 29.5 years) were enrolled in the study. The majority had proliferative LN. The mean follow-up was 85.6 ± 24.7 months. Results: CsA was used as first-line treatment in 38.7% of patients and as second-line treatment in 61.3% of patients. Complete remission was achieved in 93.5% of patients. The relapse rate was 45.2%. The mean disease-free interval was 33 months. At the end of follow-up, a total of 67.9% of the patients were in remission. The treatment led to significant improvement in proteinuria (p = 0.001) and stabilization of renal function. Conclusion: CsA might be an appropriate and a less toxic alternative drug for LN both as a first-choice and rescue therapy.

show abstract

Effects of cyclosporine in severe systemic lupus erythematosus

Cited by 64 publications

References 20 publications

Long‐term treatment of systemic lupus erythematosus with cyclosporin A

Long‐term treatment of systemic lupus erythematosus with cyclosporin A

Autoantibodies against cyclophilin in systemic lupus erythematosus and Lyme disease

Treatment of Lupus Nephritis with Cyclosporine – An Outcome Analysis

Contact Info

Product

Resources

About